TORONTO, Dec. 14, 2023 /PRNewswire/ — Quthero, a biotech company with a unique, patentedQ-peptide platform technology was accepted into the MaRS – adMare Therapeutics (Tx)Accelerator which provides a distinctive ecosystem for the development of novel therapeutics in Ontario and Canada. Quthero’s technology enables and accelerates the full regeneration of a patient’s natural tissue with minimal scarring.

“The partnership between MaRS and adMare presents Quthero with a unique opportunity to access the most experienced players in the development of new therapeutics. We are excited to bring our Q-peptide assets to the market in cardio-immunomodulatory therapeutics and dermatology” said Milica Radisic, PhD, President and CEO of Quthero. MaRS and adMare joined their expertise and resources to support the growth of therapeutics ventures in the MaRS-adMare Accelerator. “MaRS and adMare are excited to support Quthero and their team, in the first cohort of the Therapeutics (Tx) Accelerator, to bring their great science to the market and ultimately to patients.”, stated Dr. Amol Deshpande, Senior Director at MaRS DiscoveryDistrict. “A whole ecosystem is necessary to accelerate the investment and scientific readiness of therapeutic ventures. The MaRS-adMare Accelerator was created to provide an optimal environment for the growth of early-stage companies,” added Mounia Azzi, Vice President, Corporate Development at adMare BioInnovations.

Quthero has developed multiple applications for its patented Q-peptide platform technology. Quthero’s Q-peptide has been proven to speed healing, reduce redness, and prevent scarring following cosmetic and surgical procedures. It also can be used as a novel therapy for congestive heart failure.

View the full press release here.